Compare MasTec Inc (MTZ) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs Sanofi SA — how do they compare? MasTec Inc trades at $348.86 (market cap $26.60B), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Sanofi SA is far larger — about 3.9× MasTec Inc's market cap, and Sanofi SA pays a 5.5% dividend while MasTec Inc pays none. Which is the better fit depends on your goals.
| MTZ | SNY | |
|---|---|---|
Market Cap | $26.60B | $104.83B |
Sector | Technology | Health |
52-Week High | $437.51 | $52.34 |
52-Week Low | $172.51 | $41.33 |
Enterprise Value | $29.34B | $121.32B |
Dividend Yield | — | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MasTec (MTZ) trades at $336.61, up 2.13% today, amid strong analyst sentiment with 32 of 36 analysts rating it a Buy. The stock shows robust fundamentals with Q1 2026 EPS beating estimates by 40.6% and a record $20.3 billion backlog. Recent $1.65 billion acquisition of The Superior Group enhances data center infrastructure capabilities, positioning MTZ for AI-driven power demand growth. Technical indicators are bearish overall, with the stock trading near pivot point resistance at $338.
Outlook remains positive given earnings momentum and strategic expansion, though high P/E of 58.95 poses valuation risk. Upside to consensus price target of $497.45 offers 47.8% potential, but investors face execution risks from integration and debt-funded acquisitions. Revenue growth to $15.3 billion in 2026 supports bullish thesis if margins hold.
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
